Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes

Table 5 Association between lipid metabolism markers and immune cells in the microenvironment

Variable	CD3+ T cells in the CT			CD3+ T cells in the IM			CD8+ T cells in the CT			CD8+ T cells in the IM			Immunoscore
Variable	Low	High	P	Low	High	P	Low	High	P	Low	High	P	Low	High	P
CHO	4.97 (1.91–15.30)	4.90 (1.97–10.28)	0.801	5.00 (1.91–15.30)	4.82 (1.97–10.28)	0.487	4.88 (2.92–15.30)	4.88 (1.91–14.97)	0.796	4.93 (1.97–10.28)	4.86 (1.91–15.30)	0.990	4.98 (1.91–15.30)	4.80 (1.97–10.28)	0.386
TG	1.08 (0.44–4.83)	1.15 (0.52–5.82)	0.959	1.12 (0.44–4.83)	1.13 (0.52–5.82)	0.797	1.07 (0.53–4.92)	1.14 (0.44–5.82)	0.386	1.13 (0.52–5.82)	1.10 (0.44–3.76)	0.365	1.09 (0.44–4.92)	1.13 (0.52–5.82)	0.986
HDL-C	1.13 (0.59–2.73)	1.18 (0.30–2.19)	0.475	1.18 (0.59–2.73)	1.14 (0.30–2.17)	0.410	1.18 (0.68–2.73)	1.13 (0.30–2.43)	0.364	1.14 (0.30–2.19)	1.17 (0.59–2.73)	0.627	1.18 (0.59–2.73)	1.14 (0.30–2.17)	0.679
LDL-C	3.06 (0.77–13.48)	3.10 (0.80–126.10)	0.758	3.04 (0.77–13.48)	3.12 (0.80–126.10)	0.861	3.05 (0.77–126.10)	3.01 (0.80–13.48)	0.819	3.13 (0.80–126.10)	3.00 (0.77–13.48)	0.735	3.13 (0.77–126.10)	3.00 (0.80–8.56)	0.394
ApoA1	1.17 (0.58–2.06)	1.24 (0.44–2.11)	0.022	1.18 (0.58–1.77)	1.26 (0.44–2.11)	0.002	1.21 (0.58–2.11)	1.18 (0.44–2.06)	0.192	1.20 (0.44–2.06)	1.19 (0.63–2.11)	0.498	1.19 (0.58–2.06)	1.22 (0.44–2.11)	0.280
ApoB	0.97 (0.32–2.80)	0.98 (0.39–2.08)	0.828	0.97 (0.32–2.80)	0.97 (0.44–2.11)	0.929	0.97 (0.39–1.69)	0.97 (0.32–2.80)	0.408	0.97 (0.39–2.08)	0.97 (0.32–2.80)	0.832	0.98 (0.32–2.80)	0.96 (0.39–2.08)	0.801

ApoA1 apolipoprotein A1, ApoB apolipoprotein B, CHO cholesterol, CT core of the tumor, HDL high-density lipoprotein, IM invasive margin, LDL low-density lipoprotein, TG triglyceride